Search results
Results From The WOW.Com Content Network
Since November 2023, CRISPR Therapeutics has been earning approvals for Casgevy, a gene-editing medicine, in various countries and regions. This new coverage could also make it easier once CRISPR ...
Dylan Lewis: We're talking three stocks down bad. Motley Fool Money starts down. Motley Fool Money starts down. I'm Dylan Lewis, I'm joined over the airwaves by Motley Fool analyst David Meier.
Moderna's stock chart certainly looks like a falling knife. Even before the latest decline, the biotech stock was down roughly 73% since early June 2024. But is Moderna stock instead a no-brainer ...
There is still plenty of upside left for Vertex Pharmaceuticals, which makes it a top biotech stock to buy this month and hold onto for a while. 2. Moderna ... Though the stock remains down ...
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path? Geoffrey Seiler, The Motley Fool. September 15, 2024 at 5:20 AM.
The biotech stock rocketed higher last spring, but the gains didn't last long. Since reaching a peak last May, Moderna stock has tumbled by about 79%, and investors are starting to wonder if it ...
Here is why now is as good a time as any to "buy low" when it comes to this stock. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy ...
After the company revealed the pricing details of its common stock offering, shares of Moleculin Biotech Inc (NASDAQ:MBRX) tanked nearly 26% in Friday's trading session.Moleculin announced this ...